CPHI vs. KZIA, CING, NEXI, KTRA, DRUG, SNPX, TFFP, RNAZ, ARTL, and GTBP
Should you be buying China Pharma stock or one of its competitors? The main competitors of China Pharma include Kazia Therapeutics (KZIA), Cingulate (CING), NexImmune (NEXI), Kintara Therapeutics (KTRA), Bright Minds Biosciences (DRUG), Synaptogenix (SNPX), TFF Pharmaceuticals (TFFP), TransCode Therapeutics (RNAZ), Artelo Biosciences (ARTL), and GT Biopharma (GTBP). These companies are all part of the "pharmaceutical preparations" industry.
China Pharma (NYSE:CPHI) and Kazia Therapeutics (NASDAQ:KZIA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, community ranking, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.
Kazia Therapeutics received 78 more outperform votes than China Pharma when rated by MarketBeat users. Likewise, 52.35% of users gave Kazia Therapeutics an outperform vote while only 0.00% of users gave China Pharma an outperform vote.
China Pharma has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500. Comparatively, Kazia Therapeutics has a beta of 2.07, suggesting that its share price is 107% more volatile than the S&P 500.
In the previous week, China Pharma had 2 more articles in the media than Kazia Therapeutics. MarketBeat recorded 2 mentions for China Pharma and 0 mentions for Kazia Therapeutics. Kazia Therapeutics' average media sentiment score of 0.00 beat China Pharma's score of -0.38 indicating that Kazia Therapeutics is being referred to more favorably in the news media.
China Pharma has higher revenue and earnings than Kazia Therapeutics.
30.9% of Kazia Therapeutics shares are owned by institutional investors. 46.0% of China Pharma shares are owned by insiders. Comparatively, 1.0% of Kazia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Kazia Therapeutics has a net margin of 0.00% compared to China Pharma's net margin of -55.42%. Kazia Therapeutics' return on equity of 0.00% beat China Pharma's return on equity.
Summary
Kazia Therapeutics beats China Pharma on 9 of the 13 factors compared between the two stocks.
Get China Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for CPHI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CPHI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
China Pharma Competitors List
Related Companies and Tools
